A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
ConclusionNab-paclitaxel may be a safe and effective later-line chemotherapeutic option for previously treated advanced NSCLC after standard of chemotherapies based on other trials.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Abraxane | Anemia | Brain | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Hematology | Lung Cancer | Nanotechnology | Neurology | Non-Small Cell Lung Cancer | Peripheral Neuropathy | Study